Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial Article Swipe
Related Concepts
Naltrexone
Opioid use disorder
Opioid
Randomized controlled trial
Medicine
Anesthesia
Psychiatry
Psychology
Internal medicine
Receptor
Adam Bisaga
,
Paolo Mannelli
,
Miao Yu
,
Narinder Nangia
,
Christine Graham
,
D. Andrew Tompkins
,
Thomas R. Kosten
,
Sarah Akerman
,
Bernard L. Silverman
,
Maria A. Sullivan
·
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1016/j.drugalcdep.2018.02.023
· OA: W2796812403
YOU?
·
· 2018
· Open Access
·
· DOI: https://doi.org/10.1016/j.drugalcdep.2018.02.023
· OA: W2796812403
A 7-day detoxification protocol with NTX alone or NTX + BUP provided similar rates of induction to XR-NTX as placebo. For those inducted onto XR-NTX, management of opioid withdrawal symptoms prior to induction was achieved in a structured outpatient setting using a well-tolerated, fixed-dose ancillary medication regimen common to all three groups.
Related Topics
Finding more related topics…